Advances in Brief Amplification of Urokinase Gene in Prostate Cancer 1
暂无分享,去创建一个
[1] T. Visakorpi,et al. Molecular cytogenetics of prostate cancer , 2000, Microscopy research and technique.
[2] D. Slamon,et al. Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy. , 2000, Seminars in oncology.
[3] P. Russell,et al. Urokinase‐type plasminogen activator and its receptor in colorectal cancer: Independent prognostic factors of metastasis and cancer‐specific survival and potential therapeutic targets , 2000, International journal of cancer.
[4] R. Sager,et al. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin. , 2000, Cancer research.
[5] C. Larsson,et al. Characterization of chromosomal abnormalities in prostate cancer cell lines by spectral karyotyping , 2000, Cytogenetic and Genome Research.
[6] I. Bièche,et al. Quantitation of MYC gene expression in sporadic breast tumors with a real-time reverse transcription-PCR assay. , 1999, Cancer research.
[7] J. Foekens,et al. Clinical relevance of the urokinase plasminogen activator system in breast cancer , 1999, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[8] B. Nielsen,et al. Cancer invasion and tissue remodeling‐cooperation of protease systems and cell types , 1999, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[9] H. Miyake,et al. Elevation of urokinase-type plasminogen activator and its receptor densities as new predictors of disease progression and prognosis in men with prostate cancer. , 1999, International journal of oncology.
[10] T. Visakorpi,et al. Genetic alterations in hormone-refractory recurrent prostate carcinomas. , 1998, The American journal of pathology.
[11] T. Visakorpi,et al. Genetic alterations in prostate cancer cell lines detected by comparative genomic hybridization. , 1998, Cancer genetics and cytogenetics.
[12] M. Duffy,et al. The urokinase‐type plasminogen activator system in cancer metastasis: A review , 1997, International journal of cancer.
[13] E. Skrzypczak‐Jankun,et al. Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice. , 1997, Cancer research.
[14] U J Balis,et al. The LightCycler: a microvolume multisample fluorimeter with rapid temperature control. , 1997, BioTechniques.
[15] R. Sadasivan,et al. Urokinase-type plasminogen activator expression in human prostate carcinomas. , 1996, The American journal of the medical sciences.
[16] T. Visakorpi,et al. Genetic basis and clonal evolution of human prostate cancer. , 1996, Advances in cancer research.
[17] M. Maruyama,et al. Prostate‐specific antigen activates single‐chain urokinase‐type plasminogen activator , 1995, International journal of cancer.
[18] E. Hedley‐Whyte,et al. Prognostic role of urokinase-type plasminogen activator in human gliomas. , 1995, The American journal of pathology.
[19] M. Webber,et al. Urokinase-mediated extracellular matrix degradation by human prostatic carcinoma cells and its inhibition by retinoic acid. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[20] Jorma Isola,et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer , 1995, Nature Genetics.
[21] N. Brünner,et al. The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion , 1995 .
[22] E. Verrusio,et al. Enhancement of the expression of urokinase-type plasminogen activator from PC-3 human prostate cancer cells by thrombin. , 1994, Cancer research.
[23] T. Visakorpi,et al. Improved technique for analysis of formalin-fixed, paraffin-embedded tumors by fluorescence in situ hybridization. , 1994, Cytometry.
[24] A. Mazar,et al. Expression of Urokinase and Its Receptor in Invasive and Non-Invasive Prostate Cancer Cell Lines , 1992, Thrombosis and Haemostasis.
[25] J. Reynolds,et al. The Role of Plasmhogen Activators in the Regulation of Connective Tissue Metalloproteinases a , 1992 .
[26] K. Danø,et al. Plasminogen Activation by Receptor-Bound Urokinase , 1991, Seminars in thrombosis and hemostasis.
[27] F. Blasi,et al. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. , 1991, The American journal of pathology.
[28] S. Stacey,et al. Plasminogen activator inhibitors: hormonally regulated serpins , 1990, Molecular and Cellular Endocrinology.
[29] H. Keer,et al. Plasminogen activators in human prostate cancer cell lines and tumors: correlation with the aggressive phenotype. , 1989, The Journal of urology.
[30] F. Blasi,et al. Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors , 1987, The Journal of cell biology.
[31] C. Kluft,et al. Plasminogen activator inhibitors. , 1987, Blood.
[32] P. Verde,et al. Human urokinase gene is located on the long arm of chromosome 10. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[33] K. Danø,et al. immunocytochemical localization of urokinase-type plasminogen activator in lewis lung carcinoma , 1984, The Journal of cell biology.
[34] L. Liotta,et al. Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. , 1981, Cancer research.